阿利西尤单抗对急性脑梗死患者血脂和血清载脂蛋白A1水平的影响

Effect of Alirocumab on Blood Lipids and Serum Apolipoprotein A1 Levels of Patients with Acute Cerebral Infarction

目的 探讨采取阿利西尤单抗治疗急性脑梗死对患者血脂、血清载脂蛋白A1(ApoA1)的影响。方法 选取2022年1月—2023年9月本院收治的60例急性脑梗死患者为研究对象,并按照随机分组法分为观察组和对照组,每组30例。其中,对照组患者应用他汀类药物治疗,观察组在对照组的基础上加用阿利西尤单抗治疗。两组疗程均为3个月,对比两组临床治疗的效果、血脂指标[总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、ApoA1水平治疗前后变化。结果 观察组患者治疗总有效率高于对照组(P<0.05);两组患者治疗2周及治疗3个月,TC、TG、LDL-C水平都下降,而且观察组低于对照组(P<0.05);两组患者治疗2周及治疗3月,HDL-C、ApoA1指标水平均高于治疗前,且观察组高于对照组(P<0.05)。结论 使用阿利西尤单抗治疗急性脑梗死的效果令人满意,能够调节患者血脂水平,升高血清ApoA1水平。

Objective To investigate the effect of alirocumab on blood lipid and serum apolipoprotein A(ApoA1)in patients with acute cerebral infarction.Methods 60 patients with acute cerebral infarction admitted to our hospital from January 2022 to September 2023 were selected as research objects,and divided them into observation group(n=30)and control group(n=30)randomly.Control group was treated with statins,while observation group with additional Alirocumab based on control group.Treatment course of each group was 3 months.Clinical curative effect,blood lipid indicators of total cholesterol(TC),triglycerides(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),and ApoA1 levels were detected before and after treatment.Results Total effective rate of treatment in observation group was 93.33%,higher than 70.00%in control group(P<0.05).Levels of TC,TG,and LDL-C in two groups decreased after 2 weeks and 3 months of treatment,observation group had lower indicators than control group,with significant difference,(P<0.05).Levels of HDL-C and ApoA1 indicators in two groups were higher than before treatment 2 weeks and 3 months after treatment,those of observation group were higher than control group,(P<0.05).Conclusion Alirocumab can achieve satisfactory effect for acute cerebral infarction,can regulate blood lipid and increase serum ApoA1 levels of patients.